1. Home
  2. PRQR vs VYGR Comparison

PRQR vs VYGR Comparison

Compare PRQR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

HOLD

Current Price

$2.34

Market Cap

250.7M

Sector

Health Care

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.08

Market Cap

232.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRQR
VYGR
Founded
2012
2013
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.7M
232.4M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
PRQR
VYGR
Price
$2.34
$4.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
7
Target Price
$8.14
$16.17
AVG Volume (30 Days)
348.1K
468.8K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,859,556.00
$31,316,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$107.10
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$2.65
52 Week High
$3.97
$7.44

Technical Indicators

Market Signals
Indicator
PRQR
VYGR
Relative Strength Index (RSI) 53.26 43.85
Support Level $2.10 $3.91
Resistance Level $2.40 $4.30
Average True Range (ATR) 0.17 0.25
MACD 0.02 -0.00
Stochastic Oscillator 89.49 46.61

Price Performance

Historical Comparison
PRQR
VYGR

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: